Skip to content
Twitter page opens in new windowLinkedin page opens in new windowInstagram page opens in new window
info@pharmaust.com+61 8 9202 6814
PharmAust (PAA)
PharmAust (PAA)
  • HOME
  • ABOUT
    • Company Overview
    • PharmAust Management
    • Epichem Management (OHD)
    • Board
    • Corporate Directory
  • PIPELINE & TRIALS
    • Therapeutic Pipeline
    • MPL Veterinary Trial Details
    • MPL and Veterinary Trials
    • Veterinary Trial Testimonials
    • MPL and Human Trials
    • Publications
    • Pet Cancer Information Service
  • INVESTOR CENTRE
    • News & Announcements
    • Company Research
    • Financial Reports
    • Annual Reports
    • Investor Presentations
    • Corporate Governance
    • Top 20 Shareholders
  • MEDIA
    • BB PAA Video – September 2021
    • OHD Benchtop Flow Reactor Launch
    • Dr Richard Mollard – Full Interview Ticker TV – 17th June 2020
    • Interview with TechInvest – May 2020
    • Dr. Richard Mollard – 6IX Interview March 2020
    • PharmAust In the News
    • PharmAust Videos
    • PharmAust New Cancer Treatment
    • PharmAust and Catalent Commence GMP Tablet Manufacture (Audio)
    • PharmAust on Youtube
  • CONTACT
  • HOME
  • ABOUT
    • Company Overview
    • PharmAust Management
    • Epichem Management (OHD)
    • Board
    • Corporate Directory
  • PIPELINE & TRIALS
    • Therapeutic Pipeline
    • MPL Veterinary Trial Details
    • MPL and Veterinary Trials
    • Veterinary Trial Testimonials
    • MPL and Human Trials
    • Publications
    • Pet Cancer Information Service
  • INVESTOR CENTRE
    • News & Announcements
    • Company Research
    • Financial Reports
    • Annual Reports
    • Investor Presentations
    • Corporate Governance
    • Top 20 Shareholders
  • MEDIA
    • BB PAA Video – September 2021
    • OHD Benchtop Flow Reactor Launch
    • Dr Richard Mollard – Full Interview Ticker TV – 17th June 2020
    • Interview with TechInvest – May 2020
    • Dr. Richard Mollard – 6IX Interview March 2020
    • PharmAust In the News
    • PharmAust Videos
    • PharmAust New Cancer Treatment
    • PharmAust and Catalent Commence GMP Tablet Manufacture (Audio)
    • PharmAust on Youtube
  • CONTACT

Annual Reports

  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015

2021 Annual Report

Annual Reports 2021By PharmAustSeptember 16, 2021

PHARMAUST FINAL AR PDF

Read more

2020 Annual Report

Annual Reports 2020By Richard MollardDecember 1, 2020

2020-Annual Report

Read more

2019 Annual Report

Annual Reports 2019By Richard MollardSeptember 24, 2019

2019 Annual Report

Read more

2018 Annual Report

September 24, 2019

2017 Annual Report

September 24, 2019

2016 Annual Report

September 24, 2019

2015 Annual Report

September 24, 2019
MENU
  • Home
  • About Us
  • Pipeline & Trials
  • Investor Centre
  • Media
  • Contact Us
SUBSCRIBE TO OUR NEWSLETTER

TWITTER

PharmAustFollow

PharmAust is a clinical-stage biotech company developing drug discovery IP to treat cancer, viral and neurological diseases. ASX: $PAA FSE: $ECQ

PharmAust
PharmAustPharmAust@PharmAust·
18 Nov

$PAA/@PharmAust has signed agreements with NZ-based Veterinary Specialists Auckland and Intuit Regulatory, to expand its canine Phase 2b lymphoma studies into the country ahead of the upcoming Phase 3 trial.

https://stockhead.com.au/health/pharmaust-expands-studies-in-nz-one-step-closer-towards-a-phase-3-trial-for-canine-cancer/

Reply on Twitter 1461470526476455941Retweet on Twitter 14614705264764559413Like on Twitter 146147052647645594110Twitter 1461470526476455941
Load More...
Copyright © 2020 Pharmaust. All rights reserved.

Website Design & Digital Marketing Perth by Total Click Solutions

Go to Top